Amgen shares top $100 as fears fade over biosimilars

You are here: Home > Banking & Finance > Current Article

Amgen shares top $100 as fears fade over biosimilars

By Stephen Nellis / Friday, April 5th, 2013 / Comments Off on Amgen shares top $100 as fears fade over biosimilars

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

[wikichart align="center" ticker="AMGN" showannotations="true" livequote="true" startdate="04-10-2012" enddate="04-04-2013" width="390" height="245"] With its stock breaking the $100 barrier for the first time in its history, it seems the rumors of Thousand Oaks-based Amgen’s demise were greatly exaggerated. As recently as a year ago, the firm — the largest private-sector employer in Ventura County and a major source…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.